LY 3200327Alternative Names: LY3200327
Latest Information Update: 09 Nov 2015
At a glance
- Originator Eli Lilly
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Unspecified
Most Recent Events
- 02 Nov 2015 Eli Lilly plans a phase I trial in Healthy volunteers in USA (NCT02595736)
- 01 Nov 2015 Clinical trials in Undefined indication (In volunteers) in USA (SC and IV) (NCT02595736)